Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
398 active trials17 approved drugs64 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,681 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| completed |
| Phase 2 |
| 60 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jun 5, 2013 |
| clinicaltrials |
| NCT00944905 | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | completed | Phase 2 | 115 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT01381601 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics) | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT01381614 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS) | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT00112476 | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00217542 | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT01781442 | A Post Marketing Surveillance As Required By Philippine Food And Drug Administration | withdrawn | — | 0 | PfizerINDUSTRY | 0 | May 1, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | terminated | — | 4 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 15, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | Andrea HarzstarkOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00182702 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00494091 | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 82 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01441661 | Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma | completed | — | 400 | Cancer Foundation, ChinaOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00060307 | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00101114 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00601120 | RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma | withdrawn | N/A | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00816686 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer | terminated | Phase 1 | 7 | Astellas Pharma IncINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01481870 | Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma(CROSS-J-RCC) | unknown | Phase 3 | 120 | Yamagata UniversityOTHER | 1 | Feb 25, 2013 | clinicaltrials |
| NCT00087984 | RNA-Loaded Dendritic Cell Cancer Vaccine | completed | Phase 1 / Phase 2 | 26 | Argos TherapeuticsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT00619268 | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma(TORAVA) | completed | Phase 2 | 160 | Centre Leon BerardOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00032188 | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00706706 | Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma(MRCC RCC) | completed | Phase 4 | 105 | PfizerINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00006486 | Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 335 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00410124 | RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib(RECORD-1) | completed | Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 10 | Jan 15, 2013 | clinicaltrials |
| NCT00486538 | Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | completed | Phase 2 | 53 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Jan 4, 2013 | clinicaltrials |
| NCT01114230 | A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer | completed | Phase 1 | 26 | Astellas Pharma IncINDUSTRY | 1 | Dec 12, 2012 | clinicaltrials |
| NCT00513175 | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | completed | — | 44 | University of California, San FranciscoOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00065468 | Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma(ARCC) | completed | Phase 3 | 626 | PfizerINDUSTRY | 25 | Oct 25, 2012 | clinicaltrials |
| NCT00033904 | Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer | completed | Phase 3 | 650 | Agenus Inc.INDUSTRY | 11 | Sep 7, 2012 | clinicaltrials |
| NCT00126178 | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer | terminated | Phase 3 | 600 | Agenus Inc.INDUSTRY | 2 | Sep 7, 2012 | clinicaltrials |
| NCT00338884 | Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer | completed | Phase 2 | 120 | PfizerINDUSTRY | 6 | Aug 31, 2012 | clinicaltrials |
| NCT00684645 | Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT® | completed | — | 186 | PfizerINDUSTRY | 1 | Aug 21, 2012 | clinicaltrials |
| NCT00030992 | BMS 247550 to Treat Kidney Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2012 | clinicaltrials |
| NCT01158534 | Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery | completed | Phase 2 | 17 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00282048 | Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer | completed | Phase 2 | 62 | PfizerINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT01070186 | Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2012 | clinicaltrials |
| NCT00523159 | IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease(IMA901-202) | completed | Phase 2 | 68 | Immatics Biotechnologies GmbHINDUSTRY | 10 | Jul 10, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 19, 2013source: clinicaltrials